Role of purinergic receptor in alpha fodrin degradation in par C5 cells

Journal of Dental Research

Volumn 88, Issue 10, 2009, Pages 927-932

  Hwang, S M ^a   Li, J ^a   Koo, N Y ^a   Choi, S Y ^a   Lee, S J ^a   Oh, S B ^a   Castro, R ^b   Kim, J S ^a   Park, K ^a  

^a Seoul National University   (South Korea)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Alpha fodrin; P2X7 receptor; Salivary epithelial cells.; Sjo gren's syndrome

Indexed keywords

2',3' DIALDEHYDE ATP; 2',3'-DIALDEHYDE ATP; ACTIN BINDING PROTEIN; ADENOSINE TRIPHOSPHATE; AUTOANTIGEN; CALCIUM; CALPAIN; CARRIER PROTEIN; CASPASE 3; DRUG DERIVATIVE; FODRIN; MEMBRANE PROTEIN; NEUROPEPTIDE; PURINERGIC P2 RECEPTOR; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X7 RECEPTOR; SPECTRIN;

ANIMAL; APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CELL SURFACE; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM CELL; HUMAN; IMMUNOLOGY; METABOLISM; PAROTID GLAND; PATHOLOGY; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; ULTRASTRUCTURE;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; AUTOANTIGENS; CALCIUM; CALPAIN; CARRIER PROTEINS; CASPASE 3; CELL DEATH; CELL LINE; CELL SURFACE EXTENSIONS; EPITHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; NEUROPEPTIDES; PAROTID GLAND; RATS; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME; SPECTRIN;

EID: 70349644971     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/0022034509342227     Document Type: Article

References (25)

1. Bellone M. (2000). Apoptosis, cross-presentation, and the fate of the antigen specific immune response. Apoptosis 5: 307-314.
2. Jung EM, Lee TJ, Park JW, Bae YS, Kim SH, Choi YH, et al. (2008). The novel phospholipase C activator, m-3M3FBS, induces apoptosis in tumor cells through caspase activation, down-regulation of XIAP and intracellular calcium signaling. Apoptosis 13: 133-145.
3. Kahaly GJ, Bang H., Berg W., Dittmar M. (2005). Alpha-fodrin as a putative autoantigen in Gravesĝ€™ ophthalmopathy. Clin Exp Immunol 140: 166-172.
4. Li J., Ha YM, Ku NY, Choi SY, Lee SJ, Oh SB, et al. (2004). Inhibitory effects of autoantibodies on the muscarinic receptors in Sj? ¶grenĝ€™s syndrome. Lab Invest 84: 1430-1438.
5. Limesand KH, Barzen KA, Quissell DO, Anderson SM (2003). Synergistic suppression of apoptosis in salivary acinar cells by IGF1 and EGF. Cell Death Differ 10: 345-355.
6. Maniati E., Potter P., Rogers N., Morley B. (2008). Control of apoptosis in autoimmunity. J Pathol 214: 190-198.
7. Maruyama T., Saito I., Hayashi Y., Kompfner E., Fox RI, Burton DR, et al. (2004). Molecular analysis of the human autoantibody response to alpha-fodrin in Sj?¶grenĝ€™s syndrome reveals novel apoptosis-induced specificity. Am J Pathol 165: 53-61.
8. Mattson MP, Chan SL (2003). Calcium orchestrates apoptosis. Nat Cell Biol 5: 1041-1043.
9. Miyazaki K., Takeda N., Ishimaru N., Omotehara F., Arakaki R., Hayashi Y. (2005). Analysis of in vivo role of alpha-fodrin autoantigen in primary Sj?¶grenĝ€™s syndrome. Am J Pathol 167: 1051-1059.
10. Nagaraju K., Cox A., Casciola-Rosen L., Rosen A. (2001). Novel fragments of the Sj?¶grenĝ€™s syndrome autoantigens alpha-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis Rheum 44: 2376-2386.
11. Nobile M., Monaldi I., Alloisio S., Cugnoli C., Ferroni S. (2003). ATP-induced, sustained calcium signalling in cultured rat cortical astrocytes: evidence for a noncapacitative, P2X7-like-mediated calcium entry. FEBS Lett 538: 71-76.
12. North RA (2002). Molecular physiology of P2X receptors. Physiol Rev 82: 1013-1067.
13. Novak I. (2003). ATP as a signaling molecule: the exocrine focus. News Physiol Sci 18: 12-17.
14. Orrenius S., Zhivotovsky B., Nicotera P. (2003). Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 4: 552-565.
15. Routsias JG, Tzioufas AG (2007). Sj?¶grenĝ€™s syndrome-study of autoantigens and autoantibodies. Clin Rev Allergy Immunol 32: 238-251.
16. Sergeev IN, Li S., Colby J., Ho CT, Dushenkov S. (2006). Polymethoxylated flavones induce Ca(2+)-mediated apoptosis in breast cancer cells. Life Sci 80: 245-253.
17. Sisto M., Lisi S., Castellana D., Scagliusi P., Dĝ€™ Amore M., Caprio S., et al. (2006). Autoantibodies from Sj? ¶grenĝ€™s syndrome induce activation of both the intrinsic and extrinsic apoptotic pathways in human salivary gland cell line A-253. J Autoimmun 27: 38-49.
18. Surprenant A., Rassendren F., Kawashima E., North RA, Buell G. (1996). The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272: 735-738.
19. Tombal B., Denmeade SR, Gillis JM, Isaacs JT (2002). A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ 9: 561-573.
20. Wang KK (2000). Calpain and caspase: can you tell the difference? Trends Neurosci 23: 20-26 ; erratum in Trends Neurosci 23: 59, 2000.
21. Wang Q., Wang L., Feng YH, Li X., Zeng R., Gorodeski GI (2004). P2X7 receptor-mediated apoptosis of human cervical epithelial cells. Am J Physiol Cell Physiol 287: 1349-1358.
22. Wang Y., Virji AS, Howard P., Sayani Y., Zhang J., Achu P., et al. (2006). Detection of cleaved alpha-fodrin autoantigen in Sj? ¶grenĝ€™s syndrome: apoptosis and co-localisation of cleaved alpha-fodrin with activated caspase-3 and cleaved poly(ADP-ribose) polymerase (PARP) in labial salivary glands. Arch Oral Biol 51: 558-566.
23. Willeke P., Gaubitz M., Schotte H., Becker H., Mickholz E., Domschke W., et al. (2007). Clinical and immunological characteristics of patients with Sj?¶grenĝ€?s syndrome in relation to alpha-fodrin antibodies. Rheumatology (Oxford) 46: 479-483.
24. Young FM, Phungtamdet W., Sanderson BJ (2005). Modification of MTT assay conditions to examine the cytotoxic effects of amitraz on the human lymphoblastoid cell line, WIL2NS. Toxicol In Vitro 19: 1051-1059.
25. Zhang X., Zhang M., Laties AM, Mitchell CH (2005). Stimulation of P2X7 receptors elevates Ca2+ and kills retinal ganglion cells. Invest Ophthalmol Vis Sci 46: 2183-2191.